Sutent

Merck, Pfizer drug combo extends kidney cancer survival -study
Merck, Pfizer drug combo extends kidney cancer survival -study
Yahoo/Reuters
Merck
Pfizer
kidney cancer
Keytruda
Inlyta
Sutent
Flag link:
Asco-GU – Bristol’s renal cancer lead looks to be short-lived
Asco-GU – Bristol’s renal cancer lead looks to be short-lived
EP Vantage
renal cell carcinoma
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
clinical trials
Sutent
Flag link:
Merck's Keytruda, ready to challenge Bristol-Myers Squibb, posts kidney cancer combination win
Merck's Keytruda, ready to challenge Bristol-Myers Squibb, posts kidney cancer combination win
Fierce Pharma
Merck
Keytruda
kidney cancer
Pfizer
Inlyta
Sutent
Flag link:
Cancer Space Update: Label Expansion for Three Major Drugs
Cancer Space Update: Label Expansion for Three Major Drugs
Yahoo/Zacks.com
cancer
labeling
AstraZeneca
Faslodex
Pfizer
Sutent
kidney cancer
Roche
Gazyva
follicular lymphoma
Flag link:
Pfizer hits a snag in bid to jump-start Sutent's flagging kidney cancer sales
Pfizer hits a snag in bid to jump-start Sutent's flagging kidney cancer sales
Fierce Pharma
Pfizer
Sutent
kidney cancer
Flag link:
Key FDA Regulatory Events to Watch Out for in Sep 2017
Key FDA Regulatory Events to Watch Out for in Sep 2017
Yahoo/Zacks.com
FDA
Mylan Labs
Herceptin
biosimilars
trastuzumab
Shingrix
GSK
Pfizer
Sutent
PTC Therapeutics
Translarna
Amgen
Allergan
Avastin
Flag link:
What's Pfizer's Excuse for Not Buying Exelixis?
What's Pfizer's Excuse for Not Buying Exelixis?
Motley Fool
Pfizer
Exelixis
M&A
Cabometyx
kidney cancer
Sutent
Flag link:
Pfizer and Bristol-Myers Squibb Could Face a Big Threat from Small Biotech Exelixis
Pfizer and Bristol-Myers Squibb Could Face a Big Threat from Small Biotech Exelixis
Motley Fool
Pfizer
Bristol-Myers Squibb
Exelixis
Cabometyx
kidney cancer
Sutent
Opdivo
Flag link:
Exelixis and Pfizer drugs compete in kidney cancer trial
Exelixis and Pfizer drugs compete in kidney cancer trial
Yahoo/Reuters
kidney cancer
Exelixis
Pfizer
Sutent
Cabometyx
Flag link:
Pfizer's Sutent comes up big in adjuvant trial, staving off cancer for 6 years-plus
Pfizer's Sutent comes up big in adjuvant trial, staving off cancer for 6 years-plus
Fierce Pharma
Pfizer
Sutent
kidney cancer
Flag link:
Here's How Pfizer's Protecting Its Kidney Cancer Drug From New Competitors
Here's How Pfizer's Protecting Its Kidney Cancer Drug From New Competitors
Motley Fool
Pfizer
Sutent
kidney cancer
Exelixis
Bristol-Myers Squibb
Novartis
Flag link:
3 Big Pharma Stocks With Credible Threats to Their Blockbusters
3 Big Pharma Stocks With Credible Threats to Their Blockbusters
24/7 Wall St
Pfizer
renal cancer
Sutent
cabozantinib
Exelixis
AstraZeneca
Faslodex
breast cancer
Atossa Genetics
Merck
Zetia
Mylan Labs
Flag link:
What Products Affect Pfizer’s Revenue?
What Products Affect Pfizer’s Revenue?
Yahoo/Market Realist
Pfizer
Lyrica
Prevnar
Enbrel
Celebrex
Lipitor
Viagra
Zyvox
Sutent
Norvasc
Premarin
Flag link:
Pfizer Wins SUTENT® Patent Case In Delaware District Court
Pfizer Wins SUTENT® Patent Case In Delaware District Court
Yahoo
Pfizer
patents
Sutent
Delaware
Flag link:
Pfizer cancer drug Sutent linked to severe skin reactions
Pfizer cancer drug Sutent linked to severe skin reactions
CBC News
Pfizer
Sutent
cancer
Stevens Johnson Syndrome
Flag link:
Pfizer: Renal Cancer Treatment Sutent Sales Forecast
Pfizer: Renal Cancer Treatment Sutent Sales Forecast
Seeking Alpha
renal cancer
Pfizer
Sutent
Flag link:
Tackling Cancer: Kidney Cancer's Biggest Current and Upcoming Players
Tackling Cancer: Kidney Cancer's Biggest Current and Upcoming Players
Motley Fool
kidney cancer
ONYX Pharmaceuticals
Bayer
Nexavar
Roche
Avastin
Inlyta
Sutent
Pfizer
Votrient
GSK
Afinitor
Novartis
BMS-936558
Bristol-Myers Squibb
tivozanib
Aveo Oncology
Flag link:
Pfizer to challenge Indian ruling overturning cancer drug patent
Pfizer to challenge Indian ruling overturning cancer drug patent
Economic Times, India
Pfizer
Sutent
Flag link:
Drug Fails: At Least It's Approved Already
Drug Fails: At Least It's Approved Already
Motley Fool
Motley Fool
Pfizer
Torisel
Sutent
kidney cancer
Flag link:
AB Soars 46% as Cancer Drug Beats Pfizer’s Sutent: Paris Mover
AB Soars 46% as Cancer Drug Beats Pfizer’s Sutent: Paris Mover
Bloomberg
Pfizer
Sutent
AB Science
masitinib
gastrointestinal cancer
Flag link:

Pages